Cart
sales@molnova.com
SD49-7
CAS No. 54009-54-0
SD49-7( —— )
Catalog No. M35980 CAS No. 54009-54-0
SD49-7 is an inhibitor of histone lysine demethylase 4 (KDM4) with an IC50 of 0.19 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | Get Quote |
|
| 5MG | 126 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 366 | Get Quote |
|
| 50MG | 532 | Get Quote |
|
| 100MG | 744 | Get Quote |
|
| 500MG | 1485 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSD49-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionSD49-7 is an inhibitor of histone lysine demethylase 4 (KDM4) with an IC50 of 0.19 μM.
-
Description(E/Z)-NSAH is an isoform of NSAH (HY-114503), which is reversible and competitive nonnucleoside ribonucleotide reductase (RR) inhibitor, with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number54009-54-0
-
Formula Weight306.32
-
Molecular FormulaC18H14N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=NNC(=O)C1=C(O)C=CC=C1)C=2C3=C(C=CC2O)C=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Md Faiz Ahmad, et al. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246.?
molnova catalog
related products
-
CCI 007
CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485
-
T-3775440
T-3775440 is a novel potent, selecitve, irreversible LSD1 inhibitor with IC50 of 2.1 nM.
-
P3FI-63
P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.
